In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Nicte Selene Fajardo-RobledoLaboratorio de Investigación y Desarrollo Farmacéutico, Departamento de Farmacobiología, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara 44430, Jalisco, Mexico.ORCID 0000-0002-3471-5835 Heriberto Jacobo-CuevasGroup for the Assessment of Prognosis Biomarkers in Autoimmune Disorders, Centro Universitario de Ciencias de la Salud, Guadalajara 44340, Jalisco, Mexico.
Juan Manuel Ponce-GuarnerosGroup for the Assessment of Prognosis Biomarkers in Autoimmune Disorders, Centro Universitario de Ciencias de la Salud, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0001-5035-3347 Soraya Amalí Zavaleta-MuñizFacultad de Ciencias de la Salud, Universidad Juárez del Estado de Durango, Gómez Palacio 35050, Durango, Mexico.
Erika Anita Aguilar-ChavezUnidad de Medicina Familiar 2, Instituto Mexicano del Seguro Social, Guadalajara 44340, Jalisco, Mexico.
Alberto Daniel Rocha-MuñozGroup for the Assessment of Prognosis Biomarkers in Autoimmune Disorders, Centro Universitario de Ciencias de la Salud, Guadalajara 44340, Jalisco, Mexico.
Edy David Rubio-ArellanoPrograma de Doctorado en Farmacología, Departamento de Fisiología, Instituto de Terapéutica Experimental y Clínica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0002-3337-7934 Juan Manuel Viveros-ParedesLaboratorio de Investigación y Desarrollo Farmacéutico, Departamento de Farmacobiología, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara 44430, Jalisco, Mexico.ORCID 0000-0002-7532-5614 Eva Maria Olivas-FloresGroup for the Assessment of Prognosis Biomarkers in Autoimmune Disorders, Centro Universitario de Ciencias de la Salud, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0001-7192-9667 Felipe Alexis Avalos-SalgadoLaboratorio de Investigación y Desarrollo Farmacéutico, Departamento de Farmacobiología, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara 44430, Jalisco, Mexico.ORCID 0000-0001-5328-4519 Aniel Jessica Leticia Brambila-TapiaDepartamento de Psicología Básica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0002-6455-3662 Fabiola Gonzalez-PonceGroup for the Assessment of Prognosis Biomarkers in Autoimmune Disorders, Centro Universitario de Ciencias de la Salud, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0003-1932-6003 Ernesto German Cardona-MuñozGroup for the Assessment of Prognosis Biomarkers in Autoimmune Disorders, Centro Universitario de Ciencias de la Salud, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0001-7868-667X Laura Gonzalez-LopezGroup for the Assessment of Prognosis Biomarkers in Autoimmune Disorders, Centro Universitario de Ciencias de la Salud, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0002-6517-6344 Jorge Ivan Gamez-NavaGroup for the Assessment of Prognosis Biomarkers in Autoimmune Disorders, Centro Universitario de Ciencias de la Salud, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0003-0001-3787 Group for the Assessment of Prognosis Biomarkers in Autoimmune Disorders
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Lupus nephritis (LN) is a severe immune-mediated renal disorder causing significant morbidity and mortality in patients with systemic lupus erythematosus (SLE). Traditional biomarkers (serum complement components C3 and C4 and anti-dsDNA antibodies) have limited sensitivity and specificity for detecting renal flares; thus, new markers are needed to improve relapse detection and therapeutic response monitoring. We conducted a cross-sectional study including 71 women with SLE and 20 age- and sex-matched controls. Clinical data were collected, global activity was evaluated using the SLEDAI, and renal activity was evaluated using the renal SLEDAI (rSLEDAI). Serum syndecan-1 (SDC-1) and anti-dsDNA were measured using ELISA, and 24 h proteinuria was quantified. According to the rSLEDAI, 38 patients (53.5%) had LN flare, with a mean SDC-1 level of 108.5 ± 69.3 ng/mL and anti-dsDNA level of 113.1 ± 148.8 IU/mL. SDC-1 was correlated with the rSLEDAI (r = 0.32;
Indexed as
Lupus NephritisSyndecan-1AdultAntibodies, AntinuclearBiomarkersCross-Sectional StudiesFemaleHumansMiddle AgedProteinuriaAntibodies, AntinuclearBiomarkersSDC1 protein, humanSyndecan-1anti-dsDNAlupus nephritisproteinuriasensitivityspecificitysyndecan-1
Identifiers
PMID42123435
PMCPMC13164378
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390